Home

AI algorithm solves structural biology challenges

Determining the 3D shapes of biological molecules is one of the hardest problems in modern biology and medical discovery. Companies and research institutions often spend millions of dollars to determine a molecular structure - and even such massive efforts are frequently unsuccessful.

Lilly and Lycia Therapeutics enter into strategic collaboration to discover and develop novel lysosomal targeting chimera (LYTAC) degraders

Eli Lilly and Company (NYSE: LLY) and Lycia Therapeutics, Inc. today announced a multi-year research collaboration and licensing agreement focused on the discovery, development and commercialization of novel targeted therapeutics using Lycia's proprietary lysosomal targeting chimera, or LYTAC, protein degradation technology.

Gut bacteria and flavonoid-rich foods are linked and improve blood pressure levels

Flavonoid-rich foods, including berries, apples, pears and wine, appear to have a positive effect on blood pressure levels, an association that is partially explained by characteristics of the gut microbiome, according to new research published today in Hypertension, an American Heart Association journal.

AZD7442 PROVENT Phase III prophylaxis trial met primary endpoint in preventing COVID-19

Positive high-level results from the PROVENT Phase III pre-exposure prophylaxis trial showed AstraZeneca's AZD7442 achieved a statistically significant reduction in the incidence of symptomatic COVID-19, the trial's primary endpoint.

AZD7442, a combination of two long-acting antibodies (LAAB), reduced the risk of developing symptomatic COVID-19 by 77% (95% confidence interval (CI): 46, 90), compared to placebo.

Can a heartburn drug help doctors treat COVID-19?

In the early days of the COVID-19 pandemic, doctors in Wuhan noticed something surprising. Many of the elderly patients who survived the virus were poor: not exactly the demographic you would expect to fare well in a health crisis.

A review of the survivors’ medical records revealed that a significant number suffered from chronic heartburn and were taking an inexpensive drug called famotidine, the key ingredient in Pepcid.

Existing drugs kill SARS-CoV2 in cells

Since the beginning of the pandemic, researchers worldwide have been looking for ways to treat COVID-19. And while the COVID-19 vaccines represent the best measure to prevent the disease, therapies for those who do get infected remain in short supply. A new groundbreaking study from U-M reveals several drug contenders already in use for other purposes - including one dietary supplement - that have been shown to block or reduce SARS-CoV2 infection in cells.

Second-generation mRNA COVID-19 vaccine candidate, CV2CoV, demonstrates improved immune response and protection in preclinical study

CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), and GSK announced the publication of preclinical data investigating immune responses as well as the protective efficacy of CureVac's first-generation vaccine candidate, CVnCoV, and second-generation vaccine candidate, CV2CoV, against SARS-CoV-2 challenge in non-human primates.

PharmaNews.eu

AI algorithm solves structural biology challenges

Lilly and Lycia Therapeutics enter into strategic collaboration to discover and develop novel lysosomal targeting chimera (LYTAC) degraders

Gut bacteria and flavonoid-rich foods are linked and improve blood pressure levels

AZD7442 PROVENT Phase III prophylaxis trial met primary endpoint in preventing COVID-19

Can a heartburn drug help doctors treat COVID-19?

Existing drugs kill SARS-CoV2 in cells

Second-generation mRNA COVID-19 vaccine candidate, CV2CoV, demonstrates improved immune response and protection in preclinical study

More Pharma News ...